

# Thoracic Disease-Oriented Team

---

Clinical Research Treatment Flowchart

## ADVANCED/METASTATIC

■ Open to Accrual

■ Low Accruing

■ Pending Activation

1L

### UCI 24-192 (Nuvalent)

NVL-655 vs Alectinib

Mechanism: ALK inhibitor  
Coord: Mindy Chen  
PI: Dr. Nagasaka  
Accrual: 0/5

2L

### UCI 21-241 (Nuvalent)

NVL-655 + ALK inhibitor

Mechanism: ALK Inhibitor  
Coord: Keagan Buttigieg  
PI: Dr. Nagasaka  
Accrual: 20/25

### UCI 25-51 (Nuvalent)

NVL-655 EAP

Mechanism: ALK inhibitor  
Coord: To be determined  
PI: Dr. Park  
Accrual: 0/7

### Exon 18

Open to Accrual

Low Accruing

Pending Activation

### Exon 19 del or L858R

1L

**UCI 24-169**  
**(BlossomHill**  
**Therapeutics)**  
BH-30643 Capsule

Mechanism: EGFR or  
HER2 TKI  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 8/10

**UCI 24-169**  
**(BlossomHill**  
**Therapeutics)**  
BH-30643  
Capsule

Mechanism:  
EGFR or  
HER2 TKI  
Coord: Celest  
Ramirez  
PI: Dr.  
Nagasaka  
Accrual: 8/10

**UCI 24-181**  
**(Janssen**  
**Research &**  
**Development)**  
Amivantamab +  
Lazertinib  
Mechanism:  
EGFR TKI  
Coord:  
Stephanie  
Fernandez  
PI: Dr. Park  
Accrual: 1/6

**UCI 22-217**  
**(Janssen)**  
Amivantamb +  
Lazertinib w/ or  
without Carbo +  
Pemetrexed

Mechanism:  
Antibody drug w/  
TKI and Chemo  
Coord: Richard  
Chang  
PI: Dr. Nagasaka  
Accrual: 5/15

2L

**UCI 23-178**  
BL-B01D1 IV  
Mechanism:  
EGFR and/or  
HER3  
bispecific  
antibody  
Coord: Cassie  
Smith  
PI: Dr. Park  
Accrual: 5/10

## Exon 20

## Exon 21

1L

UCI 22-217(Janssen)

Amivantamb + Lazertinib w/ or  
without Carbo + Pemetrexed

Mechanism: Antibody drug w/ TKI  
and Chemo  
Coord: Richard Chang  
Dr. Nagasaka  
Accrual: 5/15

UCI 24-169  
(BlossomHill  
Therapeutics)

BH-30643 Capsule

Mechanism: EGFR  
or HER2 TKI  
Coord: Celest  
Ramirez  
Dr. Nagasaka  
Accrual: 8/10

UCI 24-169  
(BlossomHill  
Therapeutics)

BH-30643 Capsule

Mechanism:  
EGFR or HER2 TKI  
Coord: Celest  
Ramirez  
Dr. Nagasaka  
Accrual: 8/10

UCI 24-181 (Janssen Research  
& Development)

Amivantamab + Lazertinib  
Mechanism: EGFR TKI  
Coord: Stephanie Fernandez  
Dr. Park  
Accrual: 1/6

2L

## ADVANCED/METASTATIC

1L

UCI 23-66 (Boehringer  
Ingelheim)  
BI-1810631  
Monotherapy

Mechanism: TKI  
Cord: Cassie Smith  
Dr. Nagasaka  
Accrual: 2/5

2L

UCI 21-234  
T-DXd IV VS SOC (1:1)

Mechanism: NSCLC  
Harboring HER2 Exon  
19 or 20 Mutations  
(DESTINY-Lung 04)  
Accrual: 1/10

Exon 18

Exon 19

Exon 20

Exon 21

UCI 24-169 (BlossomHill Therapeutics)  
BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 8/10

UCI 23-178  
BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody  
Coord: Cassie Smith  
PI: Dr. Park  
Accrual: 5/10

## Early Stage

 Open to Accrual Low Accruing Pending ActivationUCI 25-79 (Beamion Lung-3)

Zongertinib vs SOC

Mechanism: TKI

Coord: To be determined

PI: Dr. Arter

Accrual: 0/3

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

## KRAS G12C

1L

UCI 22-30 (D3S-001-100):  
D3 Bio

Mechanism: TKI  
 Coord: Cassie Smith  
 Dr. Nagasaka  
 Accrual: 3/5

UCI 25-88 (Part A:  
Olomorasib w/ Pembro or  
Placebo w/ Pembro. Part B:  
Durvalumab w/ Pembro or  
Placebo w/ Durvalumab)

Mechanism: TKI and Anti-PD-  
 1 / Anti-PD-L1  
 Coord: TBD  
 PI: Dr. Park  
 Accrual: 0/5

2L

UCI 21-53 (Loxo Oncology,  
Inc. LOXO-RAS-20001

Mechanism: TKI  
 Coord: Mindy Chen  
 Dr. Nagasaka  
 Accrual: 9/12

## G12A, G12D, G12R, G12S, G12V

UCI 24-157 (RMC-6236-301)  
 RMC-6236 vs Docetaxel

Mechanism: TKI  
 Coord: To be determined  
 PI: Dr. Arter  
 Accrual: 0/5

UCI 22-87 (RMC-6236  
Revolution Med)

Mechanism: TKI  
 Coordinator: Jenny Choe  
 Dr. Nagasaka  
 Accrual: 21/25

ADVANCED/METASTATIC

NTRK 1-3

1L

2L

Open to Accrual

Low Accruing

Pending Activation



## ADVANCED/METASTATIC

### UCI 25-52 (PYNNAACLE)

Rezatapopt (PC14586)

Mechanism: selective P53  
reactivator

Coord: To be determined

PI: Dr. Arter

Accrual: 0/5

 Open to Accrual

 Low Accruing

 Pending Activation

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

ROS1

1L

2L

UCI 21-47 ( NVL-520 Nuvalent)

Mechanism: TKI  
Coord: Keagan Buttigieg  
PI: Dr. Nagasaka  
Accrual: 10/16

## Early Stage

 Open to Accrual Low Accruing Pending ActivationUCI 24-196 (Nuvation)

Taletrectinib vs Placebo post  
complete resection

Mechanism: ROS1 inhibitor

Coord: To be determined

Dr. Arter

Accrual: 0/5

## Advanced / Metastatic

Open to Accrual

Low Accruing

Pending Activation

1L

UCI 24-83: CB-NK +  
Atezolizumab

Mechanism: PD-L1  
Coord: Keagan Buttigieg  
PI: Dr. Villalona  
Accrual: 0/9

UCI 24-160 Chemo +  
Cemiplimab + Agent (a, b, or  
none)

Mechanism: PD-L1  
Coord: Mindy Chen  
PI: Dr. Nagasaka  
Accrual: 0/5

UCI 24-195 (Seagen/Pfizer):  
PF-08046054/SGN-PDL1V

Mechanism: PD-L1  
Coord: Keagan Buttigieg  
PI: Dr. Nagasaka  
Accrual: 0/6

2L

UCI 23-148: CJRB-01 (oral) +  
Pembrolizumab

Mechanism: Live  
biotherapeutic product +  
*Pembrolizumab*  
Coord: Mindy Chen  
PI: Dr. Nagasaka  
Accrual: 3/6

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-197 (TNG456  
Monotherapy & Combo w/  
Abemaciclib)

Mechanism:  
Coord: TBD  
PI: Dr. Park  
Accrual: 0/5

UCI 24-78 (AMG 193 Alone or  
Comb w/OtherTherapies)

Mechanism:  
Coord: Cassie Smith  
PI: Dr. Villalona  
Accrual: 1/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-138 (UCLA):  
Tarlatamab

Mechanism: BiTE molecule  
Coord: TBD  
PI: Dr. Park  
Accrual: 0/5

## Adjuvant

### UCI 23-169 (Merck V940)

Mechanism: Combo of Pembro with V940 drug to treat Stage II, IIIA, IIIB NCSLC

Coordinator: Cassie Smith  
PI: Dr. Keshava  
Accrual: 0/10

## ADVANCED/METASTATIC

### UCI 25-89 (IBI3009)

Mechanism: Recombinant Anti-DLL3 Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection

Coordinator: TBD  
PI: Dr. Arter  
Accrual: 0/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection  
Coord: Stephanie Fernandez  
PI: Dr. Nagasaka  
Accrual: 7/82

UCI 24-118 (Keshava IIT): Lung Cancer Family Screening

Mechanism: NA  
Coord: Stephanie Fernandez/  
Mindy Chen  
Accrual: 12/1753



## Advanced / Metastatic

2L

UCI 24-08 (SPEDOX-6): Dr.  
Chow IIT

Mechanism: SPE  
Coord: Erin Palmer-Torrison  
PI: Dr. Chow  
Accrual: 3/67

UCI 25-75 (CRN09682-191) :  
Crinetics Pharmaceuticals

Mechanism: NDC  
Coord: Michelle Andrade  
PI: Dr. Dayyani  
Accrual: 0/15